Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Healthcare Medical Devices
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Profound Medical Corp > Target 25 installations by YE, up from 14 as of Q2 Conf Call
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by HomerAndCompanyon Oct 07, 2021 9:49am
123 Views
Post# 33979351

RE:RE:RE:RE:RE:RE:Target 25 installations by YE, up from 14 as of Q2 Conf Call

RE:RE:RE:RE:RE:RE:Target 25 installations by YE, up from 14 as of Q2 Conf Call
MrMugsy wrote: Just listened to the Q2 again.

Today - 14 installs with 10 treating patients (USA).
20 new installs over the next 12 months.
Approximately 25 installs in the USA by end of 2021.

-----

Thanks again.


Thank you MrMugsy!

They said that they'd be doing 7-8 installations per quarter in 2022 (and then up to 10 per quarter after 2022) with the doubled (by Q3 2021) sales and installation teams. That rate of 7-8 installations per quarter must be what they ramp up to late in 2022, otherwise just 20 installs over the next 12 months seems low.
It also seems low given that they expect to go from 14 to 25 installations in the last 5 months of 2021.

Did you catch what they said about number of treatments per site and how that would evolve?

-TIA!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities